Gabriela Brunsting Hoffmann

Gabriela Brunsting Hoffmann

Auto-generated profile, based on publicly available information

Gabriela Brunsting Hoffmann

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MTMichael A Tartell
Michael A Tartell
KBKonstantinos Boulias
Konstantinos Boulias
GHGabriela Brunsting Hoffmann
Gabriela Brunsting Hoffmann
Louis-Marie BloyetLouis-Marie Bloyet
Louis-Marie Bloyet
Eric GreerEric Greer
Eric Greer
SWSean P J Whelan
Sean P J Whelan
Interferons induce cell-intrinsic responses associated with resistance to viral infection. To overcome the suppressive action of interferons and their effectors, viruses have evolved diverse mechanisms. Using vesicular stomatitis virus (VSV), we report that the host cell N6-adenosine messenger RNA (mRNA) cap methylase, phosphorylated C-terminal domain interacting factor 1 (PCIF1), attenuates the antiviral response. We employed cell-based and in vitro biochemical assays to demonstrate that PCIF1 efficiently modifies VSV mRNA cap structures to m 7 Gpppm 6 A m and define the substrate requirements for this modification. Functional assays revealed that the PCIF1-dependent modification of VSV mRNA cap structures is inert with regard to mRNA stability, translation, and viral infectivity but attenuates the antiviral effects of the treatment of cells with interferon-β. Cells lacking PCIF1 or expressing a catalytically inactive PCIF1 exhibit an augmented inhibition of viral replication and gene expression following interferon-β treatment. We further demonstrate that the mRNA cap structures of rabies and measles viruses are also modified by PCIF1 to m 7 Gpppm 6 A m . This work identifies a function of PCIF1 and cap-proximal m 6 A m in attenuation of the host response to VSV infection that likely extends to other viruses.

6 December 2022 in Blood Cancer Discovery
Verified
Journal Article
Closed access
PDF file
EHElisa Ten Hacken
Elisa Ten Hacken
TSTomasz Sewastianik
Tomasz Sewastianik
SYShanye Yin
Shanye Yin
GHGabriela Brunsting Hoffmann
Gabriela Brunsting Hoffmann
MGMichaela Gruber
Michaela Gruber
CWCatherine J. Wu
Catherine J. Wu
Transformation to aggressive disease histologies generates formidable clinical challenges across cancers, but biological insights remain few. We modeled the genetic heterogeneity of chronic lymphocytic leukemia (CLL) through multiplexed in vivo CRISPR-Cas9 B-cell editing of recurrent CLL loss-of-function drivers in mice and recapitulated the process of transformation from indolent CLL into large cell lymphoma [i.e., Richter syndrome (RS)]. Evolutionary trajectories of 64 mice carrying diverse combinatorial gene assortments revealed coselection of mutations in Trp53, Mga, and Chd2 and the dual impact of clonal Mga/Chd2 mutations on E2F/MYC and interferon signaling dysregulation. Comparative human and murine RS analyses demonstrated tonic PI3K signaling as a key feature of transformed disease, with constitutive activation of the AKT and S6 kinases, downmodulation of the PTEN phosphatase, and convergent activation of MYC/PI3K transcriptional programs underlying enhanced sensitivity to MYC/mTOR/PI3K inhibition. This robust experimental system presents a unique framework to study lymphoid biology and therapy. Significance: Mouse models reflective of the genetic complexity and heterogeneity of human tumors remain few, including those able to recapitulate transformation to aggressive disease histologies. Herein, we model CLL transformation into RS through multiplexed in vivo gene editing, providing key insight into the pathophysiology and therapeutic vulnerabilities of transformed disease. This article is highlighted in the In This Issue feature, p. 101

11 August 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
EHElisa Ten Hacken
Elisa Ten Hacken
SYShanye Yin
Shanye Yin
RRRobert Redd
Robert Redd
Jesús María Hernández-RivasJesús María Hernández-Rivas
Jesús María Hernández-Rivas
KCKendell Clement
Kendell Clement
CWCatherine J. Wu
Catherine J. Wu

5 November 2021 in Blood
Verified
Journal Article
Open access
EHElisa Ten Hacken
Elisa Ten Hacken
SYShanye Yin
Shanye Yin
TSTomasz Sewastianik
Tomasz Sewastianik
LPLivius Penter
Livius Penter
NRNeil Ruthen
Neil Ruthen
CWCatherine J. Wu
Catherine J. Wu
Richter's syndrome (RS) represents one of the foremost challenges in CLL management, and its pathogenesis remains largely undefined. We recently leveraged CRISPR-Cas9 in vivo gene editing to develop mouse models of RS by engineering multiplexed loss-of-function lesions typical of CLL (Atm, Trp53, Chd2, Birc3, Mga, Samhd1) in early stem and progenitor cells [Lineage - Sca-1 + c-kit + (LSK)] from MDR-Cd19Cas9 donor mice. These animals express Cas9-GFP in a B-cell restricted fashion and the leukemogenic MDR lesion, which mimics del(13q) when the sgRNA-transduced LSK cells are transplanted in CD45.1 immunocompetent recipients. Through these methods, we observed not only development of CLL, but also transformation into RS, and even captured a stage where CLL and RS were co-existing in the same animal (CLL/RS). We hypothesized that the molecular events underlying RS development would be markedly distinct from those of CLL and performed transcriptome analysis of FACS-sorted CLL and/or RS cells (5 CLL, 4 CLL/RS, 10 RS) and normal B cell controls from 4 age-matched wild type MDR-Cd19Cas9 mice. We identified a unique transcriptional profile of RS (ANOVA, FDR100 commonly altered genes including upregulated cell cycle regulators (CDK1, CCNA2) and downregulated signaling adapters (ITPKB, MAP3K9). To further dissect gene regulatory networks driving transformation in the mouse, we profiled one CLL and one RS case by single cell ATAC sequencing (scATAC-seq). Consistent with the RNA-seq profiles, we detected increased chromatin accessibility of MYC-family associated transcription factor motifs (MAX, MYCN), and reduced accessibility of the pro-inflammatory STAT2 motif in RS (-log10adjP>50). Functionally, decreased interferon gamma responses were confirmed by the reduced ability of RS cells to phosphorylate STAT1 and STAT3 at 5' and 15' after IFN-gamma stimulation, compared to CLL and normal B cells (Western Blot). To define the genetic landscape underlying these changes, we performed whole genome sequencing analysis, and identified loss of chr12 and chr16 as recurrent events in RS (6/8 cases) and CLL/RS (2/2), but not in CLL cases (0/5). Among the genes encoded by these chromosomes, we identified several epigenetic drivers (Dnmt3a, Crebbp, Setd3/4), MAP kinase family members (Map4k5, Mapk1), cytoskeletal regulators (Hcls1, Rhoj), and interferon family receptors (Ifnar1/2, Ifngr2), suggesting that broad epigenetic modifications together with loss of BCR and interferon signaling molecules represent key events of transforming disease. RS cases were also characterized by a significantly higher number of full chromosome amplifications or deletions (median=6; range: 2-9), as compared to CLL or CLL/RS (1; 0-5, P=0.0008), consistent with the high degree of genomic instability observed in human disease. Finally, we asked whether the observed changes would impact RS therapeutic vulnerabilities, and exposed 15 primary murine RS splenocyte samples to 20 drugs in vitro for 24 hours, followed by CellTiter-Glo assessment of cellular viability. We observed strong sensitivity to the BRD4 inhibitor JQ1 and the mTOR inhibitor everolimus (both reported to interfere with MYC signaling, P<0.0001), and to CDK inhibitors (e.g. the CDK4/6 inhibitor palbociclib, P=0.0007), modest activity of the JAK1/2 inhibitor ruxolitinib (P=0.05), and minimal, if any, response to ibrutinib, venetoclax and fludarabine. In conclusion, we define the evolutionary trajectories and therapeutic vulnerabilities of RS in a mouse model, with unique transcriptional, genetic, and epigenetic features, indicative of broad changes in MYC, IFN and BCR signaling pathways and remarkable similarities with human disease. In-depth analyses of BCR signaling and in vivo treatment studies are underway and will refine mechanistic insights into the biology of RS.

24 November 2025
Verified
Other
Open access
EHElisa Ten Hacken
Elisa Ten Hacken
TSTomasz Sewastianik
Tomasz Sewastianik
SYShanye Yin
Shanye Yin
GHGabriela Brunsting Hoffmann
Gabriela Brunsting Hoffmann
MGMichaela Gruber
Michaela Gruber
CWCatherine J. Wu
Catherine J. Wu
Supplementary file contains all supplementary tables S1-S16 in Excel format in the order in which they appear in the text.

4 April 2023
Verified
Other
Open access
EHElisa Ten Hacken
Elisa Ten Hacken
TSTomasz Sewastianik
Tomasz Sewastianik
SYShanye Yin
Shanye Yin
GHGabriela Brunsting Hoffmann
Gabriela Brunsting Hoffmann
MGMichaela Gruber
Michaela Gruber
CWCatherine J. Wu
Catherine J. Wu
Supplementary file contains all supplementary tables S1-S16 in Excel format in the order in which they appear in the text.